At what hemoglobin level should apixaban (Eliquis) be held?

Apixaban Should Be Held for Major Bleeding Defined by Hemoglobin Drop ≥2 g/dL

Hold apixaban when there is clinically overt bleeding with a hemoglobin decrease ≥2 g/dL or when ≥2 units of red blood cells have been administered 1. This threshold defines major bleeding and triggers immediate discontinuation of the anticoagulant.

Clinical Decision Algorithm

Major Bleeding Criteria (Hold Apixaban)

Stop apixaban immediately if ANY of the following apply:

• Hemoglobin drop ≥2 g/dL with clinically overt bleeding
• Transfusion of ≥2 units of RBCs required
• Bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, retroperitoneal)
• Hemodynamic instability

1

Non-Major Bleeding (Consider Holding)

For non-major bleeding without the above criteria, you may continue apixaban if there is an appropriate indication, though holding is reasonable while implementing local hemostatic measures 1.

Management After Holding

Once you've stopped apixaban for major bleeding:

1. Provide supportive care including volume resuscitation and local hemostatic measures
2. Consider reversal agents for life-threatening or critical site bleeding:
   • Andexanet alfa is the specific reversal agent for apixaban 2, 3
   • Use when DOAC levels >50-75 ng/mL and bleeding is uncontrolled 2
3. Assess for contributing factors: thrombocytopenia, uremia, liver disease, concomitant antiplatelet therapy 1

Important Caveats

Baseline anemia matters: Patients with baseline hemoglobin <13 g/dL (men) or <12 g/dL (women) have nearly double the risk of major bleeding on apixaban (adjusted HR 1.92) 4. In these patients, even smaller absolute drops may represent proportionally significant bleeding.

Concomitant antiplatelet therapy dramatically increases bleeding risk: In dialysis patients, 86% of those with bleeding events were on concurrent antiplatelet therapy versus only 6% without bleeding 5. Consider stopping antiplatelet agents when holding apixaban for bleeding 1.

GI bleeding context: For gastrointestinal bleeding specifically, the hemoglobin drop ≥2 g/dL threshold remains the standard for defining major bleeding requiring apixaban discontinuation 6. However, many GI bleeds can be managed with local supportive measures without requiring specific reversal agents 2.

When NOT to Hold

Do not hold apixaban for:

• Elective surgery (plan ahead with 24-48 hour interruption) 7
• High DOAC levels without associated bleeding 2
• Minor bleeding that doesn't meet major bleeding criteria and can be controlled with local measures 1